Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.35 |
| ▸ | STK3 | Q13188 | 4/20 | 0.33 |
| ▸ | STK4 | Q13043 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019486 | 0.80 | CHEK1 (0.61) | CHEK1NOTUMAURKAAKT1STK3 | |
| SCHEMBL1598149 | 0.79 | CHEK1 (0.66) | CHEK1NOTUMAURKAAKT1TRPA1 | |
| SCHEMBL31329069 | 0.79 | CHEK1 (0.66) | CHEK1NOTUMAURKAAKT1TRPA1 | |
| SCHEMBL153752 | 0.78 | CHEK1 (0.63) | CHEK1NOTUMAURKAAKT1STK3 | |
| SCHEMBL2323682 | 0.78 | CHEK1 (0.63) | CHEK1NOTUMAURKAAKT1STK3 | |
| SCHEMBL154600 | 0.76 | CHEK1 (0.61) | CHEK1NOTUMAURKAAKT1DYRK1A | |
| SCHEMBL61206 | 0.76 | CHEK1 (1.00) | CHEK1NOTUMAURKAAKT1STK3 | |
| SCHEMBL357993 | 0.76 | CHEK1 (0.61) | CHEK1NOTUMAURKAAKT1TRPA1 | |
| SCHEMBL3236479 | 0.76 | CHEK1 (0.56) | CHEK1NOTUMAURKASTK3STK4 | |
| SCHEMBL155227 | 0.74 | CHEK1 (0.54) | CHEK1NOTUMCYP3A4CYP2C19JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050342-B2 | Beneficial effects of combination therapy on cholesterol | PFIZER INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-1666481-B9 | 3-((3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitrile as protein kinase inhibitor | PFIZER PROD INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120252825-A1 | BENEFICIAL EFFECTS OF COMBINATION THERAPY ON CHOLESTEROL | PFIZER INC. (US) | 2012-10-04 | — | — | US | disclosed |
| EP-1666481-B1 | 3-((3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitrile as protein kinase inhibitor | PFIZER PROD INC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-1609781-B1 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine | PFIZER PROD INC (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7842699-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-RE41783-E1 | Immunosuppressants; organ transplant; CP 690550 which is 3-(4-Methyl-3-(methyl-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-amino)-piperidin-1-yl)-3-oxo-propionitrile; inhibitors of the enzyme protein kinases such as Janus Kinase 3 | PFIZER INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20100035903-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | BLUMENKOPF TODD A | 2010-02-11 | — | — | US | disclosed |
| US-7601727-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1294724-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | Pfizer Products Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002096909-A1 | OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1235830-A2 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2002000661-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| US-20010053782-A1 | Immunosuppressants; organ transplant | BLUMENKOPF TODD A (US) | 2001-12-20 | — | — | US | disclosed |
| WO-2001042246-A2 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1087971-A1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065909-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035903-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | JAK3, JAK1, PDXK | CHEK1 370/4885NOTUM 3361/4885AURKA 633/4885 |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | CHEK1 112/4885NOTUM 3502/4885AURKA 163/4885 |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | CHEK1 403/4885NOTUM 3508/4885AURKA 397/4885 |
| US-20120252825-A1 | BENEFICIAL EFFECTS OF COMBINATION THERAPY ON CHOLESTEROL | HMGCR, LDLR, PCSK9 | CHEK1 2668/4885NOTUM 786/4885AURKA 1342/4885 |
| US-20010053782-A1 | Immunosuppressants; organ transplant | JAK1, JAK3, TPMT | CHEK1 1321/4885NOTUM 2742/4885AURKA 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.